{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:36:38Z","timestamp":1777430198667,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.ophtha.2010.04.016","type":"journal-article","created":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T04:51:15Z","timestamp":1280897475000},"page":"111-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Ranibizumab for Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration: A Phase I Clinical Trial"],"prefix":"10.1016","volume":"118","clinical-trial-number":[{"clinical-trial-number":"nct00395551","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jeffrey S.","family":"Heier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ciulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prema","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy M.","family":"Bankert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Paul E.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana K.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2010.04.016_bib1","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0002-9394(14)73649-9","article-title":"Age-related macular degeneration and choroidal neovascularization","volume":"115","author":"Freund","year":"1993","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.016_bib2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s004170050360","article-title":"Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate","volume":"238","author":"Cui","year":"2000","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.016_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00941723","article-title":"Expression of vascular endothelial growth factor in experimental choroidal neovascularization","volume":"235","author":"Ishibashi","year":"1997","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.016_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00417-003-0838-y","article-title":"Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium","volume":"242","author":"Martin","year":"2004","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.016_bib5","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.4.564","article-title":"Prevalence of age-related macular degeneration in the United States","volume":"122","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.016_bib6","first-page":"1508","article-title":"Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration","volume":"113","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2010.04.016_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2010.04.016_bib8","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2010.04.016_bib9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0161-6420(02)01998-X","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3","volume":"110","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2010.04.016_bib10","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archopht.122.11.1597","article-title":"Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I","volume":"122","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.016_bib11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1001\/archopht.1991.01080080069030","article-title":"Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.016_bib12","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/eye.2009.88","article-title":"Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results","volume":"23","author":"Mones","year":"2009","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2010.04.016_bib13","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IAE.0b013e31819ed6bd","article-title":"Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia","volume":"29","author":"Lai","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2010.04.016_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00417-008-0995-0","article-title":"Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization","volume":"247","author":"Konstantinidis","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.016_bib15","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/bjo.2008.145391","article-title":"Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome","volume":"93","author":"Ruiz-Moreno","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.016_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/bjo.2008.143461","article-title":"Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularisation in patients with angioid streaks","volume":"93","author":"Wiegand","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.016_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ajo.2007.09.025","article-title":"Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration","volume":"145","author":"Nguyen","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.016_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.016_bib19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642010004446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642010004446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:00:27Z","timestamp":1758981627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642010004446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0161642010004446"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2010.04.016","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ranibizumab for Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration: A Phase I Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2010.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}